Revised SPC: Vizimpro (dacomitinib) tablets

SPC now states that the starting dose should be adjusted to 30 mg once daily in patients with severe (Child-Pugh class C) hepatic impairment. The dose may be increased to 45 mg once daily based on individual safety and tolerability after at least 4 weeks of treatment.

Source:

electronic Medicines compendium